All News

This week, top managed care stories included an additional setback for Medicaid work rules; another study finding more benefits from SGLT2 inhibitors; researchers finding unwanted end-of-life care causes stress.

Circulation, a peer-reviewed journal of the American Heart Association, just released its fourth annual Go Red for Women issue, in which researchers from the Smidt Heart Institute at Cedars-Sinai note the stark disparities in how heart disease manifests in women and men. For women, sudden cardiac death is often the first sign they even have heart disease.

In 2019, the US Department of Defense (DoD) and Department of Veterans Affairs (VA) approved clinical practice guidelines regarding management and treatment of chronic insomnia disorder and obstructive sleep apnea in VA and DoD patients. The VA/DoD Evidence-Based Practice Work Group formulated the framework to enable more effective screening, treatment, and managements of these diseases, according to a review published in Annals of Internal Medicine.

Cardinal Innovations Healthcare is the largest specialty health plan in the country, insuring more than 850,000 North Carolinians with complex needs. Using a community-based model of care management, Cardinal Innovations has led the way in developing services, processes and solutions that improve the lives of our members and their families. Recognized for operational excellence, innovative solutions and superior outcomes for members, accuracy and speed of payments to providers, and cost-effective funds management, Cardinal Innovations is a leading healthcare company in the United States.

Radium-223’s (Ra-223) low levels of alpha particle radiation induce double-strand DNA breaks, which leads to cell apoptosis. Sipuleucel-T (SipT), which is an immunotherapy manufactured from a patient’s peripheral blood mononuclear cells, activates T cells to spur an immune response. Both are used to treat bone-metastatic castration-resistant prostate cancer (CRPC). Study data suggest a synergistic immune effect when Ra-223 is added to treatment with SipT.

According to recent study results published in JAMA, treatment-limiting Physician Orders for Life-Sustaining Treatment (POLSTs) were significantly associated with lower rates of intensive care unit admissions among patients with life-limiting conditions compared with patients who had full-treatment POLSTs. However, researchers found 38% of patients with treatment-limiting POLSTs still received intensive care that was potentially discordant with their preferences.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo